Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Muth · SciRah

Researcher profile · Semantic Scholar

M. Muth

Share profile

M. Muth — researcher profile on SciRah

h-index: 8
Works: 30
Citations: 212

Most-cited papers

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
H. Tesch, O. Stoetzer, T. Decker, C. Kurbacher +13 more
2018International Journal of Cancer47 citations Open access
Semantic Scholar
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study
Peyman Hadji, Anette Kauka, M. Ziller, K. Birkholz +3 more
2014Osteoporosis International29 citations
Semantic Scholar
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
P. Fasching, S. Jud, M. Hauschild, S. Kümmel +19 more
2014BMC Cancer25 citations Open access
Semantic Scholar
LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO
P. Fasching, T. Decker, A. Schneeweiss, C. Uleer +16 more
201423 citations Open access
Semantic Scholar
Role of TDM‐based dose adjustments for taxane anticancer drugs
M. Muth, F. W. Ojara, C. Kloft, M. Joerger
2020British Journal of Clinical Pharmacology15 citations
Semantic Scholar
Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer
N. Maass, C. Schem, D. Bauerschlag, K. Tiemann +10 more
2014Oncology14 citations Open access
Semantic Scholar
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study
P. Hadji, A. Kauka, M. Ziller, K. Birkholz +3 more
2014Breast Cancer Research and Treatment13 citations
Semantic Scholar
Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.
D. Lueftner, F. Schuetz, E. Grischke, P. Fasching +9 more
201410 citations
Semantic Scholar
Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)
H. Tesch, O. Stoetzer, T. Decker, C. Kurbacher +14 more
20156 citations
Semantic Scholar
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
P. Hadji, O. Stoetzer, T. Decker, C. Kurbacher +13 more
2018Journal of Bone Oncology5 citations Open access
Semantic Scholar
Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women"
C. Jackisch, E. Grischke, A. Schneeweiss, T. Decker +16 more
20155 citations
Semantic Scholar
Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results
P. Fasching, S. Jud, M. Hauschild, S. Kümmel +8 more
20125 citations
Semantic Scholar
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
P. Hadji, M. Ziller, T. Maurer, M. Autenrieth +8 more
2012Journal of Bone Oncology4 citations Open access
Semantic Scholar
P2-19-03: Influence of Zoledronic Acid on BMD in Premenopausal Women with Breast Cancer and Neoadjuvant or Adjuvant Chemotherapy and/or Endocrine Treatment – The ProBone Studies.
P. Hadji, A. Kauka, T. Bauer, M. Kalder +5 more
20114 citations
Semantic Scholar
4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients.
P. Fasching, W. Gumbrecht, T. Fehm, L. Haeberle +16 more
20133 citations
Semantic Scholar
Abstract OT2-6-09: 4EVER - A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)
H. Tesch, P. Fasching, P. Hadji, D. Lueftner +8 more
20131 citations
Semantic Scholar
The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
Peyman Hadji, M. Ziller, Tobias Maurer, M. Muth +4 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
14 Influence of zoledronic acid on bone mineral density in premenopausal women with hormone receptor positive or negative breast cancer and neoadjuvant or adjuvant chemotherapy or endocrine treatment
P. Hadji, A. Kauka, M. Kalder, T. Bauer +3 more
20091 citations
Semantic Scholar
Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)
P. Hadji, H. Tesch, O. Stoetzer, T. Decker +14 more
20150 citations
Semantic Scholar
Retraction Statement. Paper by Manizate et al., entitled ‘Liver functional reserve estimation: state of the art and relevance to local treatments‘ Oncology 2010;78(suppl 1):131-134, DOI: 10.1159/000315241
Cathy Mast, R. Ramanathan, D. Feinstein, P. Rosen +59 more
2014Oncology0 citations Open access
Semantic Scholar
Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO
E. Grischke, D. Lüftner, F. Schütz, P. Wimberger +9 more
20140 citations
Semantic Scholar
Effects of zoledronic acid on hormone levels in premenopausal women with breast cancer receiving neoadjuvant or adjuvant chemotherapy and endocrine therapy: Probone II Study
P. Hadji, Anette Kauka, T. Bauer, M. Ziller +4 more
20130 citations
Semantic Scholar
Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?
P. Hadji, H. Tesch, P. Fasching, D. Lueftner +8 more
20130 citations
Semantic Scholar
Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer: the ZOTECT Study
P. Hadji, M. Ziller, T. Maurer, M. Autenrieth +8 more
20130 citations
Semantic Scholar
Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study
P. Hadji, Anette Kauka, T. Bauer, K. Birkholz +3 more
20130 citations
Semantic Scholar
BRAWO - Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women
D. Lüftner, H. Tesch, F. Schütz, W. Bloch +3 more
20130 citations
Semantic Scholar
Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC).
C. Mundhenke, C. Schem, D. Bauerschlag, M. Weigel +8 more
20120 citations
Semantic Scholar
OT3-01-02: Imatinib Mesylate in Combination with Vinorelbine for Patients with Metastatic Breast Cancer – An Ongoing Phase I/II Clinical Trial.
C. Mundhenke, C. Schem, D. Bauerschlag, M. Weigel +8 more
20110 citations
Semantic Scholar
THE ZOTECT STUDY: EFFECT OF INTRAVENOUS ZOLEDRONIC ACID ON BONE METABOLISM IN PATIENTS WITH METASTATIC BONE DISEASE IN BREAST CANCER AND PROSTATE CANCER
J. Gschwend, M. Ziller, M. Kalder, M. Muth +3 more
20100 citations
Semantic Scholar
The Zotect study: Effect of zoledronic acid (Zometa (R)) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.
J. Gschwendt, M. Ziller, M. Kalder, C. Lux +4 more
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Hadji×14
Invite
P. Hadji — researcher profile on SciRah
H. Tesch×12
Invite
H. Tesch — researcher profile on SciRah
T. Decker×11
Invite
T. Decker — researcher profile on SciRah
P. Fasching×11
Invite
P. Fasching — researcher profile on SciRah

×11

Invite

J. Kreuzeder — researcher profile on SciRah

C. Mundhenke×10

Invite

C. Mundhenke — researcher profile on SciRah

A. Schneeweiss×9

Invite

A. Schneeweiss — researcher profile on SciRah

Invite

M. Ziller — researcher profile on SciRah

Invite

M. Baier — researcher profile on SciRah

Invite

M. Lux — researcher profile on SciRah

Invite

K. Birkholz — researcher profile on SciRah

Invite

D. Lüftner — researcher profile on SciRah